Amsterdam to host EMA
The relocation is a direct consequence of the UK’s decision to leave the European Union, and the Commission is now following-on with the legal work for relocation, with work to ensure that EMA staff loses are minimal, and with work to maintain our high European standards for the regulation of medicines and medicinal products.
Denmark’s stronghold in Life Sciences and the pharmaceutical industry means that we take a European and global approach. In this regard, Amsterdam is a solid alternative to London to host the EMA - as would fx Stockholm, Milan or Copenhagen had been.
We are looking forward to continued collaborations with our friends and colleagues in the Dutch pharmaceutical and biotech organisations and clusters, and we wish for a smooth transition of the EMA.
Read the EMA Press Release at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/11/WC500238862.pdf